SCHEMBL2408930

SCHEMBL2408930

O=C(O)c1cc(C(=O)O)cc(-c2cc(Cl)ccc2O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
ALOX15 P16050 2/20 0.45
TSHR P16473 1/20 0.45
TPMT P51580 1/20 0.45
SRD5A2 P31213 2/20 0.45
AURKA O14965 1/20 0.44
TPX2 Q9ULW0 1/20 0.44
TP53 P04637 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HCAR1 Q9BXC0 1/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406313 0.85 RXRA (0.58) CA1CA2ALOX15TP53MAPT
SCHEMBL8779218 0.80 SRD5A2 (0.68) ALOX15TSHRTPMTSRD5A2AURKA
SCHEMBL14273027 0.79 TSHR (0.55) CA1CA2ALOX15TSHRSRD5A2
SCHEMBL2403560 0.77 CA1 (0.76) CA1CA2TP53ALDH1A1MEN1
SCHEMBL2410383 0.77 ALDH1A1 (0.57) CA1CA2TPMTALDH1A1MEN1
SCHEMBL6851115 0.76 TPMT (0.52) CA1CA2ALOX15TSHRTPMT
SCHEMBL2406306 0.76 CA1 (0.62) CA1CA2TSHRTP53ALDH1A1
SCHEMBL6849600 0.76 ALDH1A1 (0.56) CA1CA2ALOX15TSHRTP53
SCHEMBL29383789 0.75 BACE1 (0.62) CA1CA2ALOX15TSHRTP53
SCHEMBL329155 0.75 BACE1 (0.62) CA1CA2ALOX15TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
US-20090176973-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2009-07-09 US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885
US-20090176973-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK CA1 4586/4885CA2 4818/4885ALOX15 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.